Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  I-SENS Inc    A099190   KR7099190001

I-SENS INC

(A099190)
  Report
No quotes available
-- KRW   --.--%
 SummaryRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2020 209 B
EBIT 2020 34,0 B
Net income 2020 26,0 B
Finance 2020 37,0 B
Yield 2020 0,65%
Sales 2021 226 B
EBIT 2021 39,8 B
Net income 2021 32,1 B
Finance 2021 59,1 B
Yield 2021 0,65%
P/E ratio 2020 12,1x
P/E ratio 2021 9,94x
EV / Sales2020 1 509x
EV / Sales2021 1 398x
Capitalization 315 B
More Financials
Company
i-SENS, Inc. is a Korea-based company mainly engaged in the manufacture and sale of biosensors. The Company’s products consist of blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the... 
More about the company
Surperformance© ratings of i-SENS Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on I-SENS INC

- No features available -

More news
News in other languages on I-SENS INC

- No features available -

More news
Sector news : Medical Equipment
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
More sector news : Medical Equipment
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 34 500,00  KRW
Last Close Price 23 200,00  KRW
Spread / Highest target 55,2%
Spread / Average Target 48,7%
Spread / Lowest Target 42,2%
EPS Revisions
Managers
NameTitle
Geun-Sig Cha Chief Executive Officer & Director
Hak-Hyun Nam President, Director, Head-Research & Development
Young-Chool Song Independent Director
Jong-Woo Youn Director & Managing Director
Sung-Jin Hwang Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
I-SENS INC266
ABBOTT LABORATORIES3.22%157 180
MASIMO CORPORATION16.14%9 730
NOVOCURE LIMITED12.74%9 403
PENUMBRA, INC.16.29%6 670
ASAHI INTECC CO., LTD.-11.85%6 596